Nano-curcumin enhances the sensitivity of tamoxifen-resistant breast cancer cells via the Cyclin D1-DILA1 axis and the PI3K/AKT/mTOR pathway downregulation
PLOS One · 2025
DOI: 10.1371/journal.pone.0335165 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Taraneh Givi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran. Hauptthemen laut MEDLINE: Curcumin, Cyclin D1, Tamoxifen, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tarbiat Modares University.
Abstract (Originalsprache)
This research investigates the effects of nano-curcumin on the expression of Cyclin D1 and DILA1 genes, as well as on the PI3K/AKT/mTOR pathway, in tamoxifen-sensitive and resistant MCF-7 breast cancer cell lines. The IC50 values were determined using the MTT assay. To establish tamoxifen-resistant MCF7 cells, a stepwise exposure to tamoxifen was conducted, gradually increasing the concentration to twice the IC50 dose. Following treatment with nano-curcumin, cell migration, proliferation, and apoptosis were evaluated using a wound healing assay and flow cytometry. Additionally, the impact of nano-curcumin on the PI3K/AKT/mTOR and Cyclin D1 signaling pathways was analyzed via qRT-PCR and Western blot. Nano-curcumin treatment significantly inhibits cell proliferation, viability, and migration and promotes apoptosis in tamoxifen-sensitive and resistant MCF7 cell lines. qRT-PCR and Western blot analyses revealed reduced expression of Cyclin D1, DILA1, NF- κ B, PI3K, AKT, mTOR, VEGF α, MMP2 , and BCL2 , along with increased levels of PTEN, TIMP3, RECK , and BAX . Our results indicate that nano-curcumin mitigates drug resistance by decreasing DILA1 expression, which destabilizes Cyclin D1 protein and downregulates PI3K/AKT/mTOR pathway genes. Additionally, nano-curcumin induces apoptosis and inhibits migration. These findings suggest the nano-curcumin and tamoxifen combination may be a promising therapeutic strategy to overcome drug resistance in ER+ breast malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.
- Food and Drug Laboratory Research Center, Food and Drug Administration, MOH MOE, Tehran, Iran.
ORCID-Profile: Mohammadjavad Karimi Taheri, Sadegh Babashah, Majid Sadeghizadeh
Förderung
- Tarbiat Modares University
Zitieren
APA
Givi, T., Mohajerani, F., Tehrankhah, Z. M., Karimi Taheri, M., Amirahmadi, M., Babashah, S., & Sadeghizadeh, M. (2025). Nano-curcumin enhances the sensitivity of tamoxifen-resistant breast cancer cells via the Cyclin D1-DILA1 axis and the PI3K/AKT/mTOR pathway downregulation. PLOS One. https://doi.org/10.1371/journal.pone.0335165
Vancouver
Givi T, Mohajerani F, Tehrankhah ZM, Karimi Taheri M, Amirahmadi M, Babashah S, et al. Nano-curcumin enhances the sensitivity of tamoxifen-resistant breast cancer cells via the Cyclin D1-DILA1 axis and the PI3K/AKT/mTOR pathway downregulation. PLOS One. 2025. doi:10.1371/journal.pone.0335165
BibTeX
@article{Givi2025,
author = {Givi, Taraneh and Mohajerani, Fatemeh and Tehrankhah, Zahra Moazezi and Karimi Taheri, Mohammadjavad and Amirahmadi, Maryam and Babashah, Sadegh and Sadeghizadeh, Majid},
title = {Nano-curcumin enhances the sensitivity of tamoxifen-resistant breast cancer cells via the Cyclin D1-DILA1 axis and the PI3K/AKT/mTOR pathway downregulation},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0335165}
}
EUVIMED